Tenofovir monotherapy versus tenofovir plus lamivudine or telbivudine combination therapy in treatment of lamivudine-resistant chronic hepatitis B

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 2, 2015, Pages 972-978

  Lee, Yun Bin ^a,d   Jung, Eun Uk ^b   Kim, Bo Hyun ^c   Lee, Jeong Hoon ^a   Cho, Hyeki ^a   Ahn, Hongkeun ^a   Choi, Won Mook ^a   Cho, Young Youn ^a   Lee, Minjong ^a   Yoo, Jeong Ju ^a   Cho, Yuri ^a   Lee, Dong Hyeon ^a   Cho, Eun Ju ^a   Yu, Su Jong ^a   Park, Sung Jae ^b   Kim, Yoon Jun ^a   Park, Joong Won ^a   Lee, Youn Jae ^b   Kim, Chang Min ^c   Yoon, Jung Hwan ^a   Kim, Chung Yong ^a   Lee, Hyo Suk ^a   more..

^a Seoul National University College of Medicine   (South Korea)

^b Inje University College of Medicine   (South Korea)

^c National Cancer Center   (South Korea)

^d CHA University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; DNA; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PHOSPHORUS; TELBIVUDINE; TENOFOVIR DISOPROXIL; ADENINE; ANTIVIRUS AGENT; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENETIC RESISTANCE; GENETIC VARIABILITY; HEPATITIS B; HUMAN; HYPOPHOSPHATEMIA; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY (TOPIC); MUSCLE WEAKNESS; MYALGIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SELECTION BIAS; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; VIROLOGY; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; HEPATITIS B, CHRONIC; MULTICENTER STUDY; TREATMENT OUTCOME;

ADENINE; ADULT; AGED; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; RETROSPECTIVE STUDIES; TENOFOVIR; TREATMENT OUTCOME;

EID: 84921925999     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04454-14     Document Type: Article

References (33)

1. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J. 2004. Lamivudine for patients with chronic hepatitisBand advanced liver disease.NEngl J Med 351:1521-1531. http://dx.doi.org/10.1056/NEJMoa033364.
2. European Association for the Study of the Liver 2012. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 57:167-185.
3. Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, Brown N, Woessner M, Boehme R, Condreay L. 2003. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 36:687-696. http://dx.doi.org/10.1086 /368083.
4. Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M. 2007. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 133:1445-1451. http://dx.doi.org/10.1053/j.gastro.2007.08.079.
5. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. 2007. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 45:307-313. http://dx.doi.org/10.1002 /hep.21534.
6. Lok AS, McMahon BJ. 2007. Chronic hepatitis B. Hepatology 45:507-539. http://dx.doi.org/10.1002/hep.21513.
7. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S. 2008. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2:263-283. http://dx.doi.org/10.1007/s12072-008-9080-3.
8. Seto WK, Liu K, Fung J, Wong DK, Yuen JC, Hung IF, Lai CL, Yuen MF. 2012. Outcome of lamivudine-resistant chronic hepatitis B after up to 5 years of combination therapy with adefovir. Antivir Ther 17:1255-1262. http://dx.doi.org/10.3851/IMP2335.
9. Zoulim F, Locarnini S. 2009. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 137:1593-1608, e1591- e1592. http://dx.doi .org/10.1053/j.gastro.2009.08.063.
10. Delaney WE, IV, Ray AS, Yang H, Qi X, Xiong S, Zhu Y, Miller MD. 2006. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother 50:2471-2477. http://dx .doi.org/10.1128/AAC.00138-06.
11. Lada O, Benhamou Y, Cahour A, Katlama C, Poynard T, Thibault V. 2004. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. Antivir Ther 9:353-363.
12. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Washington MK, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F. 2008. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 359:2442-2455. http://dx.doi .org/10.1056/NEJMoa0802878.
13. Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Gurel S, Snow-Lampart A, Borroto-Esoda K, Mondou E, Anderson J, Sorbel J, Rousseau F. 2011. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 140:132-143. http://dx.doi.org/10.1053/j.gastro.2010.10.011.
14. Snow-Lampart A, Chappell B, Curtis M, Zhu Y, Myrick F, Schawalder J, Kitrinos K, Svarovskaia ES, Miller MD, Sorbel J, Heathcote J, Marcellin P, Borroto-Esoda K. 2011. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology 53:763-773. http://dx .doi.org/10.1002/hep.24078.
15. van Bömmel F, de Man RA, Wedemeyer H, Deterding K, Petersen J, Buggisch P, Erhardt A, Huppe D, Stein K, Trojan J, Sarrazin C, Bocher WO, Spengler U, Wasmuth HE, Reinders JG, Moller B, Rhode P, Feucht HH, Wiedenmann B, Berg T. 2010. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 51:73-80. http://dx .doi.org/10.1002/hep.23246.
16. Fung S, Kwan P, Fabri M, Horban A, Pelemis M, Hann HW, Gurel S, Caruntu FA, Flaherty JF, Massetto B, Dinh P, Corsa A, Subramanian GM, McHutchison JG, Husa P, Gane E. 2014. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 146:980-988. http://dx.doi.org/10.1053/j.gastro.2013.12.028.
17. Corsa AC, Liu Y, Flaherty JF, Mitchell B, Fung SK, Gane E, Miller MD, Kitrinos KM. 2014. No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B. Clin Gastroenterol Hepatol 12:2106-2112.e1. http: //dx.doi.org/10.1016/j.cgh.2014.05.024.
18. Lok AS, McMahon BJ. 2009. Chronic hepatitis B: update 2009. Hepatology 50:661-662. http://dx.doi.org/10.1002/hep.23190.
19. Zoulim F, Locarnini S. 2012. Management of treatment failure in chronic hepatitis B. J Hepatol 56(Suppl 1):S112-S122.
20. Chevaliez S, Bouvier-Alias M, Laperche S, Hezode C, Pawlotsky JM. 2010. Performance of version 2.0 of the Cobas AmpliPrep/Cobas TaqMan real-time PCR assay for hepatitis B virus DNA quantification. J Clin Microbiol 48:3641-3647. http://dx.doi.org/10.1128/JCM.01306-10.
21. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, Condreay LD. 1998. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 27:1670-1677.
22. Kim HS, Han KH, Ahn SH, Kim EO, Chang HY, Moon MS, Chung HJ, Yoo W, Kim SO, Hong SP. 2005. Evaluation of methods for monitoring drug resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization. Antivir Ther 10: 441-449.
23. Rosenbaum PR, Rubin DB. 1983. The central role of the propensity score in observational studies for causal effects. Biometrika 70:41-55. http://dx .doi.org/10.1093/biomet/70.1.41.
24. Curtis LH, Hammill BG, Eisenstein EL, Kramer JM, Anstrom KJ. 2007. Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases. Med Care 45:S103-S107. http: //dx.doi.org/10.1097/MLR.0b013e31806518ac.
25. Patterson SJ, George J, Strasser SI, Lee AU, Sievert W, Nicoll AJ, Desmond PV, Roberts SK, Locarnini S, Bowden S, Angus PW. 2011. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut 60:247-254. http://dx.doi.org/10.1136/gut.2010.223206.
26. Weintraub WS, Grau-Sepulveda MV, Weiss JM, O'Brien SM, Peterson ED, Kolm P, Zhang Z, Klein LW, Shaw RE, McKay C, Ritzenthaler LL, Popma JJ, Messenger JC, Shahian DM, Grover FL, Mayer JE, Shewan CM, Garratt KN, Moussa ID, Dangas GD, Edwards FH. 2012. Comparative effectiveness of revascularization strategies. N Engl J Med 366: 1467-1476. http://dx.doi.org/10.1056/NEJMoa1110717.
27. Feld JJ, Heathcote EJ. 2006. Hepatitis B e antigen-positive chronic hepatitis B: natural history and treatment. Semin Liver Dis 26:116-129. http: //dx.doi.org/10.1055/s-2006-939750.
28. Pol S, Lampertico P. 2012. First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practice. J Viral Hepat 19:377-386. http://dx.doi.org/10.1111/j.1365-2893 .2012.01602.x.
29. Berg T, Zoulim F, Moeller B, Trinh H, Marcellin P, Chan S, Kitrinos KM, Dinh P, Flaherty JF, Jr, McHutchison JG, Manns M. 2014. Longterm efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients. J Hepatol 60:715-722. http://dx.doi.org/10.1016/j.jhep.2013.11.024.
30. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Schall RA, Bornstein JD, Kitrinos KM, Subramanian GM, McHutchison JG, Heathcote EJ. 2013. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 381:468-475. http://dx.doi.org/10.1016/S0140-6736(12)61425-1.
31. Verhelst D, Monge M, Meynard JL, Fouqueray B, Mougenot B, Girard PM, Ronco P, Rossert J. 2002. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 40:1331-1333. http://dx.doi.org/10.1053/ajkd.2002.36924.
32. Woodward CL, Hall AM, Williams IG, Madge S, Copas A, Nair D, Edwards SG, Johnson MA, Connolly JO. 2009. Tenofovir-associated renal and bone toxicity. HIV Med 10:482-487. http://dx.doi.org/10.1111 /j.1468-1293.2009.00716.x.
33. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK. 2004. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292:191-201. http://dx.doi.org /10.1001/jama.292.2.191.